循环中的端粒酶逆转录酶（TERT）可作为可切除非小细胞肺癌（NSCLC）的新型诊断和预后生物标志物。
Circulating TERT serves as the novel diagnostic and prognostic biomarker for the resectable NSCLC.
作者信息
Chen Guanxuan, Wang Shiwen, Zhang Qianru, Liu Junyan, Zhu Wanqi, Song Xianrang, Song Xingguo
机构信息
Oncology Department, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, PR China.
Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, 440 Ji- Yan Road, Jinan, 250117, Shandong Province, PR China.
出版信息
Cancer Cell Int. 2024 Dec 19;24(1):420. doi: 10.1186/s12935-024-03605-w.
BACKGROUND
Telomerase reverse transcriptase (TERT) is a catalytic subunit of telomerase and required for cancer development. This study aims to reveal its clinical utility for diagnosis and prognosis of resectable NSCLC.
METHODS
TERT was quantitatively evaluated by the enzyme-linked immunosorbent assay (ELISA) from 69 patients before and after the surgery. The prognostic value was evaluated by disease-free survival (DFS) and overall survival (OS).
RESULTS
Circulating TERT in NSCLC patients were significantly higher than that in the healthy group, possessing the AUC of 0.90. Importantly, TERT change between pre- and post- operation was significantly correlated with OS and DFS (p = 0.022, p = 0.046 respectively), acted as the independent prognostic factors for DFS and OS, indicating it can serve as the promising diagnostic and prognostic biomarker for resectable non-small cell lung cancer (NSCLC).
CONCLUSIONS
TERT change between pre- and post- resection can serve as the promising biomarker for prognosis of resectable NSCLC.
背景
端粒酶逆转录酶（TERT）是端粒酶的催化亚基，是癌症发展所必需的。本研究旨在揭示其在可切除非小细胞肺癌诊断和预后中的临床应用价值。
方法
采用酶联免疫吸附测定（ELISA）对69例患者手术前后的TERT进行定量评估。通过无病生存期（DFS）和总生存期（OS）评估预后价值。
结果
非小细胞肺癌患者的循环TERT显著高于健康组，曲线下面积（AUC）为0.90。重要的是，手术前后TERT的变化与OS和DFS显著相关（分别为p = 0.022，p = 0.046），是DFS和OS的独立预后因素，表明它可作为可切除非小细胞肺癌（NSCLC）有前景的诊断和预后生物标志物。
结论
切除前后TERT的变化可作为可切除非小细胞肺癌预后的有前景的生物标志物。
Zotero 插件